A NOVEL GLYCOMIC BASED SERUM BIOMARKER (GLYCOCIRRHOTEST) FOR RISK ASSESSMENT OF HEPATOCELLULAR CARCINOMA IN COMPENSATED CIRRHOSIS

(1) Hepatology and Gastroenterology,Ghent University Hospital,Ghent,Belgium;Laboratory of Hepatology,Ghent University,Ghent,Belgium

(2) Inflammation Research Center,Vlaams Instituut voor Biotechnologie,Ghent,Armenia

(3) Department of Hepatology,Beaujon University Hospital,Clichy,France

(4) Inflammation Research Center,Vlaams Instituut voor Biotechnologie,Ghent,Belgium



This item was part of UEG Week 2015

This item can be cited as: United European Gastroenterology Journal; 2015: 2 (Supplement 1)

You may be interested in:

In which patients with ALD and NAFLD can we avoid liver biopsy?
English, Presentation, Clinical aspects, Investigation and Diagnosis, Classification, Liver, Alcoholic liver disease, Elastography, NAFLD / NASH, Hepatology, 2012
Non-invasive assessment of liver fibrosis
Presentation, 2014, Hepatobiliary
Beta blockers for bleeding prophylaxis
English, Presentation, Hepatobiliary, 2016, Radiology & Imaging

Categorisation:

  • Format
    • Abstract
  • Year
    • 2015